Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)

HKG:9637 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jul 15, 2026	Dec 31, 2025	Dec 31, 2024
Debt / Equity Ratio	1.09	1.09	-0.36
Net Debt / Equity Ratio	0.04	0.04	-0.08
Net Debt / EBITDA Ratio	-0.03	-0.03	-0.37
Net Debt / FCF Ratio	-0.04	-0.04	-0.23
Asset Turnover	0.03	0.03	-
Inventory Turnover	2.09	2.09	-
Quick Ratio	2.22	2.22	0.19
Current Ratio	2.33	2.33	0.20
Return on Assets (ROA)	-33.01%	-33.01%	-
Return on Capital Employed (ROCE)	-58.80%	-58.80%	37.20%
Buyback Yield / Dilution	-	10.08%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 13, 2026

Data Sources Report a data error